期刊名称：INFLAMMOPHARMACOLOGY ISSN： 0925-4692 出版频率： Bi-monthly 出版社： SPRINGER BASEL AG, PICASSOPLATZ 4, BASEL, SWITZERLAND, 4052   出版社网址： http://link.springer.com/ 期刊网址： http://link.springer.com/journal/10787 影响因子： 4.473 主题范畴： IMMUNOLOGY;    TOXICOLOGY 变更情况： 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Inflammopharmacology Experimental and Therapeutic Studies Editor-in-Chief: K. D. Rainsford ISSN: 0925-4692 (print version) ISSN: 1568-5608 (electronic version) Journal no. 10787 Description Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS).Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn's disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, and arthritic conditions. The journal has five main interest areas: Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress statesRheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugsGastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agentsNeuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and painNovel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs.Requirements for manuscripts on the pharmacological or inflammatory properties of, natural products are described in the editorial Inflammopharmacology Vol. 15, issue 5 or on the journal website: www.springer.com/10787.   Reviews all aspects of inflammation and its pharmacological control Compares different inflammatory states, and their causes Examines the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions Covers Conditional Pharmacology/Toxicology, Rheumatology, Gastroenterology, Pulmonary Inflammation and Novel Drugs, Natural Products and Nutraceuticals Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn's disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, and arthritic conditions. The journal has five main interest areas:  Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs. Requirements for manuscripts on the pharmacological or inflammatory properties of natural products are described in the editorial Inflammopharmacology Vol. 15, issue 5 or on the journal website: www.springer.com/10787. Related subjects » Dermatology - Immunology - Internal Medicine - Pharmacology & Toxicology - Rheumatology Abstracted/Indexed in  PubMed/Medline, SCOPUS, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, EBSCO, CSA, Academic OneFile, Academic Search, Biological Abstracts, BIOSIS, ChemWeb, CSA Environmental Sciences, Elsevier Biobase, Gale, Health Reference Center Academic, OCLC, SCImago, Summon by Serial Solutions Popular Content within this publication    7 days 30 days 90 days   Ibuprofen: pharmacology, efficacy and safetyRainsford, K. D. A review of the pharmacological effects of Arctium lappa (burdock)Chan, Yuk-Shing; Cheng, Long-Ni; Wu, Jian-Hong; Chan, Enoch; Kwan, Yiu-Wa; Lee, Simon Ming-Yuen; Leung, George Pak-Heng; Yu, Peter Hoi-Fu; Chan, Shun-Wan Show all authors (9)Hide authors The musculoskeletal abnormalities of the Similaun Iceman (“ÖTZI”): clues to chronic pain and possible treatmentsKean, Walter F.; Tocchio, Shannon; Kean, Mary; Rainsford, K. D. Show all authors (4)Hide authors Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitisThomas, Saskia; Baumgart, Daniel C. Interdisciplinary review for correlation between the plant origin capsaicinoids, non-steroidal antiinflammatory drugs, gastrointestinal mucosal damage and prevention in animals and human beingsMózsik, Gyula; Past, Tibor; Abdel Salam, Omar M. E.; Kuzma, Mónika; Perjési, Pál Show all authors (5) Aims and scope: Inflammopharmacology Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn's disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, and arthritic conditions. The journal has five main interest areas:  Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs. Requirements for manuscripts on the pharmacological or inflammatory properties of natural products are described in the editorial Inflammopharmacology Vol. 15, issue 5 or on the journal website: www.springer.com/10787.   Scope of Inflammopharmacology Acute and chronic inflammatory processes underlie a vast number of diseases. These processes involve production of many inflammatory mediators, which are formed from or interact with a wide range of cells, including those of the immune system, to cause various responses at specific sites in the body. This presents challenges for drug treatment of these conditions and for the effectiveness of conventional agents such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying anti-rheumatic drugs (DMARDs), anti-cytokine and other biologic agents, as well as natural products (or nutraceuticals). The use of many of these agents is often limited by (a) the agents’ unspecific actions or limited potency at their therapeutic targets, (b) their poor pharmacokinetic properties leading to poor bioavailability of the active agents, and (c) their varying array of serious and non-serious side-effects and adverse drug reactions. Broadly speaking, Inflammopharmacology aims to publish high quality papers addressing these key problems and directed towards “advancing research into new medicines” as well as new approaches to development of safer and more effective, site-specific anti-inflammatory agents. The prime focus of papers considered for inclusion in the journal is concentrated on the mechanisms of action and the use of anti-inflammatory agents in the treatment of rheumatic and related painful conditions. The journal also aims to publish papers on the fundamental and clinical aspects of the iatrogenic conditions that accompany treatment with many anti-rheumatic agents including those involving the gastro-intestinal, hepato-renal and cardiovascular systems. Papers concerned with the beneficial effects of anti-inflammatory drugs in the prevention of cancer, Alzheimer’s and other neurodegenerative diseases are of particular interest for publication in this journal. One of the central elements in understanding the modes of action of various anti-inflammatory agents is the recognition that drugs may be limited in their effectiveness, selectivity and toxicology as a consequence of the disease processes themselves. These “disease-drug interactions“, can differ depending on the disease states being treated. This area of increasing interest being described as “conditional pharmacology”, i.e. disease state(s) may influence drug actions and vice versa (see Inflammopharmacology 1991; 1:61; 1995; 3:363). With the widening use of NSAIDs in the treatment of neurodegenerative diseases, etc. reflect an obvious need for a multi-disciplinary journal, such as Inflammopharmacology. This diagram gives a perspective of scope and content of articles in Inflammopharmacology. Click here to enlarge the picture The journal welcomes suggestions of other topics that might fall within its area of interest to widen both its attractiveness to authors and increase its readership. K.D. Rainsford Editor-in-Chief   Instructions to Authors Types of papers  Manuscripts can be in the form of (a) full length publications of Original Research Papers; they should not be longer than 8 printed pages. This accounts for approx. 870 words (or 4700 characters, plain text without spaces) per printed page. Figures and tables have to be counted in addition. (b) Short Communications or notes on methodology or findings (with positive or negative outcome) complete in themselves, (c) Reviews, they should not be longer than 12 printed pages (d) Commentaries (as Points of View), (e) Letters to the Editor, or (f) invited or contributed Editorials. All manuscripts must be in English. Editorial procedure  Editorial procedure Papers should be original and unpublished or considered for publication elsewhere. A statement to this effect should be made in the accompanying letter submitted with the manuscript. It is the responsibility of the principal author to secure requisite permission from his or her employer and all papers submitted are understood to have received due clearance(s) for publication. In general an author may quote briefly from other published works but he or she should obtain permission from the holder of copyright if wishing to use substantial extracts or to reproduce tables, plates, or other illustrations. If the copyright-holder is not the author of the quoted or reproduced material, it is recommended that the permission of the author should also be sought. Permission to reproduce copyright material should be submitted with the manuscript. Material in unpublished letters and papers is also protected and must not be published unless permission has been obtained. A suitable acknowledgement of any quoted or reproduced material must always be made. All manuscripts will be reviewed anonymously by at least two independent reviewers not connected (as much as this is practicable) with one another. Reviewers will be given a simple question and answer analysis sheet to complete. Where exceptional comment is required this can be noted. Stylistic queries or those concerning the English or presentation of the manuscript will be noted by underlining in red pen of the relevant part or section and the manuscripts will be returned to the author(s) annotated as such. It will not be the task of reviewers to exhaustively point out errors of syntax or spelling in the text, since this is time consuming. Acceptance of the manuscript will depend on the accuracy in presentation. The reviewers will only correct errors of English in special cases where English is clearly not the mother tongue of the authors. In all other cases language correction will take place after the manuscript has been accepted. The Editor’s decisions on acceptance shall be final. Manuscript submission  Manuscript Submission Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation. Permissions Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors. Online Submission Authors should submit their manuscripts online. Electronic submission substantially reduces the editorial processing and reviewing times and shortens overall publication times. Please follow the hyperlink “Submit online” on the right and upload all of your manuscript files following the instructions given on the screen. Title page  Title Page The title page should include: The name(s) of the author(s) A concise and informative title The affiliation(s) and address(es) of the author(s) The e-mail address, telephone and fax numbers of the corresponding author Abstract Please provide an abstract of 150 to 250 words. The abstract should not contain any undefined abbreviations or unspecified references. Keywords Please provide 4 to 6 keywords which can be used for indexing purposes. Text  Text Formatting Manuscripts should be submitted in Word. Use a normal, plain font (e.g., 10-point Times Roman) for text. Use italics for emphasis. Use the automatic page numbering function to number the pages. Do not use field functions. Use tab stops or other commands for indents, not the space bar. Use the table function, not spreadsheets, to make tables. Use the equation editor or MathType for equations. Save your file in docx format (Word 2007 or higher) or doc format (older Word versions). Headings Please use no more than three levels of displayed headings. Abbreviations Abbreviations should be defined at first mention and used consistently thereafter. Footnotes Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables. Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or the authors of the article are not given reference symbols. Always use footnotes instead of endnotes. Acknowledgments Acknowledgments of people, grants, funds, etc. should be placed in a separate section before the reference list. The names of funding organizations should be written in full. Specific Remarks Introduction The Introduction should be short, up to a maximum of 2/3 of a printed page, containing essential background information and a concise statement of the objectives of the study. Text The Methods & Materials section should be detailed in such a way that the reader could perform the study without undue recourse to an extensive literature: the exception being for well-known methods (e.g. protein estimation using the Lowry method) which can be referenced. Where noncommercial sources of reagents, antibodies etc. have been employed their preparation should be detailed as much as practicable. Where patented procedures, reagents or antibodies have been employed, these should be cited as such. Since patents constitute information in the public domain there is no reason why full details cannot be abstracted. The same data should not be given in both text and tables or figures and tables. Results should be presented in either tables or graphs with full details of statistical tests employed. Authors may be asked to provide original data if there is a question of controversy together with a detailed work-up of statistical analysis. Justification for the use of parametric or non-parametric statistical procedures should be employed where there is any doubt as to the model employed. The Discussion and Conclusions should be laid out as follows: (1) main conclusions and interpretation of results from the study, (2) an analysis of how the results conform to a published hypothesis or that formulated in the introduction, (3) a comprehensive discussion of how the results relate to other published observations, (4) a conclusions statement should include a balanced view of what the work has shown bearing in mind the review in the introduction, (5) acknowledgements and statement of sources of funding and any conflicts of interest should be included, and (6) references (see below). Discussions and Conclusions should be restricted to a maximum of one printed page. It should be noted that the selective use of published work to reinforce the prejudiced idea or results of the author will not be accepted. The literature review, while concise, should be comprehensive, even if there are results of others which are contradictory or controversial. Symbols and Abbreviations Units of measurement, abbreviations and symbols should follow the International System of Units (SI). For chemical nomenclature, the conventions of the International Union of Pure and Applied Chemistry and the official recommendations of the IUPAC -- IUB Combined Commission on Biochemical Nomenclature should be followed. References  Citation Cite references in the text by name and year in parentheses. Some examples: Negotiation research spans many disciplines (Thompson 1990). This result was later contradicted by Becker and Seligman (1996). This effect has been widely studied (Abbott 1991; Barakat et al. 1995; Kelso and Smith 1998; Medvec et al. 1999). Reference list The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text. Do not use footnotes or endnotes as a substitute for a reference list. Reference list entries should be alphabetized by the last names of the first author of each work. Journal article Gamelin FX, Baquet G, Berthoin S, Thevenet D, Nourry C, Nottin S, Bosquet L (2009) Effect of high intensity intermittent training on heart rate variability in prepubescent children. Eur J Appl Physiol 105:731-738. doi: 10.1007/s00421-008-0955-8 Ideally, the names of all authors should be provided, but the usage of “et al” in long author lists will also be accepted: Smith J, Jones M Jr, Houghton L et al (1999) Future of health insurance. N Engl J Med 965:325–329 Article by DOI Slifka MK, Whitton JL (2000) Clinical implications of dysregulated cytokine production. J Mol Med. doi:10.1007/s001090000086 Book South J, Blass B (2001) The future of modern genomics. Blackwell, London Book chapter Brown B, Aaron M (2001) The politics of nature. In: Smith J (ed) The rise of modern genomics, 3rd edn. Wiley, New York, pp 230-257 Online document Cartwright J (2007) Big stars have weather too. IOP Publishing PhysicsWeb. http://physicsweb.org/articles/news/11/6/16/1. Accessed 26 June 2007 Dissertation Trent JW (1975) Experimental acute renal failure. Dissertation, University of California Always use the standard abbreviation of a journal’s name according to the ISSN List of Title Word Abbreviations, see www.issn.org/2-22661-LTWA-online.php For authors using EndNote, Springer provides an output style that supports the formatting of in-text citations and reference list. EndNote style (zip, 3 kB) Please note The citation-style explained above is in accordance with the Harvard style. If a publication is in press, the references should be made as complete as possible, e.g. stating the name of the journal adding “in press” and if available a DOI number. Tables  All tables are to be numbered using Arabic numerals. Tables should always be cited in text in consecutive numerical order. For each table, please supply a table caption (title) explaining the components of the table. Identify any previously published material by giving the original source in the form of a reference at the end of the table caption. Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data) and included beneath the table body. Artwork and Illustrations Guidelines  For the best quality final product, it is highly recommended that you submit all of your artwork – photographs, line drawings, etc. – in an electronic format. Your art will then be produced to the highest standards with the greatest accuracy to detail. The published work will directly reflect the quality of the artwork provided. Electronic Figure Submission Supply all figures electronically. Indicate what graphics program was used to create the artwork. For vector graphics, the preferred format is EPS; for halftones, please use TIFF format. MS Office files are also acceptable. Vector graphics containing fonts must have the fonts embedded in the files. Name your figure files with "Fig" and the figure number, e.g., Fig1.eps. Line Art Definition: Black and white graphic with no shading. Do not use faint lines and/or lettering and check that all lines and lettering within the figures are legible at final size. All lines should be at least 0.1 mm (0.3 pt) wide. Scanned line drawings and line drawings in bitmap format should have a minimum resolution of 1200 dpi. Vector graphics containing fonts must have the fonts embedded in the files. Halftone Art Definition: Photographs, drawings, or paintings with fine shading, etc. If any magnification is used in the photographs, indicate this by using scale bars within the figures themselves. Halftones should have a minimum resolution of 300 dpi. Combination Art Definition: a combination of halftone and line art, e.g., halftones containing line drawing, extensive lettering, color diagrams, etc. Combination artwork should have a minimum resolution of 600 dpi. Color Art Color art is free of charge for online publication. If black and white will be shown in the print version, make sure that the main information will still be visible. Many colors are not distinguishable from one another when converted to black and white. A simple way to check this is to make a xerographic copy to see if the necessary distinctions between the different colors are still apparent. If the figures will be printed in black and white, do not refer to color in the captions. Color illustrations should be submitted as RGB (8 bits per channel). Figure Lettering To add lettering, it is best to use Helvetica or Arial (sans serif fonts). Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 mm (8–12 pt). Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type on an axis and 20-pt type for the axis label. Avoid effects such as shading, outline letters, etc. Do not include titles or captions within your illustrations. Figure Numbering All figures are to be numbered using Arabic numerals. Figures should always be cited in text in consecutive numerical order. Figure parts should be denoted by lowercase letters (a, b, c, etc.). If an appendix appears in your article and it contains one or more figures, continue the consecutive numbering of the main text. Do not number the appendix figures, "A1, A2, A3, etc." Figures in online appendices (Electronic Supplementary Material) should, however, be numbered separately. Figure Captions Each figure should have a concise caption describing accurately what the figure depicts. Include the captions in the text file of the manuscript, not in the figure file. Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type. No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the caption. Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs. Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption. Figure Placement and Size When preparing your figures, size figures to fit in the column width. For most journals the figures should be 39 mm, 84 mm, 129 mm, or 174 mm wide and not higher than 234 mm. For books and book-sized journals, the figures should be 80 mm or 122 mm wide and not higher than 198 mm. Permissions If you include figures that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant electronic rights for free and that Springer will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used. Accessibility In order to give people of all abilities and disabilities access to the content of your figures, please make sure that All figures have descriptive captions (blind users could then use a text-to-speech software or a text-to-Braille hardware) Patterns are used instead of or in addition to colors for conveying information (color-blind users would then be able to distinguish the visual elements) Any figure lettering has a contrast ratio of at least 4.5:1 Electronic Supplementary Material  Springer accepts electronic multimedia files (animations, movies, audio, etc.) and other supplementary files to be published online along with an article or a book chapter. This feature can add dimension to the author's article, as certain information cannot be printed or is more convenient in electronic form. Submission Supply all supplementary material in standard file formats. Please include in each file the following information: article title, journal name, author names; affiliation and e-mail address of the corresponding author. To accommodate user downloads, please keep in mind that larger-sized files may require very long download times and that some users may experience other problems during downloading. Audio, Video, and Animations Always use MPEG-1 (.mpg) format. Text and Presentations Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability. A collection of figures may also be combined in a PDF file. Spreadsheets Spreadsheets should be converted to PDF if no interaction with the data is intended. If the readers should be encouraged to make their own calculations, spreadsheets should be submitted as .xls files (MS Excel). Specialized Formats Specialized format such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), and .tex can also be supplied. Collecting Multiple Files It is possible to collect multiple files in a .zip or .gz file. Numbering If supplying any supplementary material, the text must make specific mention of the material as a citation, similar to that of figures and tables. Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the animation (Online Resource 3)", “... additional data are given in Online Resource 4”. Name the files consecutively, e.g. “ESM_3.mpg”, “ESM_4.pdf”. Captions For each supplementary material, please supply a concise caption describing the content of the file. Processing of supplementary files Electronic supplementary material will be published as received from the author without any conversion, editing, or reformatting. Accessibility In order to give people of all abilities and disabilities access to the content of your supplementary files, please make sure that The manuscript contains a descriptive caption for each supplementary material Video files do not contain anything that flashes more than three times per second (so that users prone to seizures caused by such effects are not put at risk) After acceptance  Upon acceptance of your article you will receive a link to the special Author Query Application at Springer’s web page where you can sign the Copyright Transfer Statement online and indicate whether you wish to order OpenChoice, offprints, or printing of figures in color. Once the Author Query Application has been completed, your article will be processed and you will receive the proofs. Open Choice In addition to the normal publication process (whereby an article is submitted to the journal and access to that article is granted to customers who have purchased a subscription), Springer provides an alternative publishing option: Springer Open Choice. A Springer Open Choice article receives all the benefits of a regular subscription-based article, but in addition is made available publicly through Springer’s online platform SpringerLink. Springer Open Choice Copyright transfer Authors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher exclusive publication and dissemination rights). This will ensure the widest possible protection and dissemination of information under copyright laws. Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under the Creative Commons Attribution License. Offprints Offprints can be ordered by the corresponding author. Color illustrations Online publication of color illustrations is free of charge. For color in the print version, authors will be expected to make a contribution towards the extra costs. Proof reading The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor. After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article. Online First The article will be published online after receipt of the corrected proofs. This is the official first publication citable with the DOI. After release of the printed version, the paper can also be cited by issue and page numbers. Ethical standards  Manuscripts submitted for publication must contain a statement to the effect that all human and animal studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or failure to fulfill the above-mentioned requirements Please note Authors should note that Inflammopharmacology complies with the recommendations of the Committee on Publishing Ethics (COPE) http://publicationethics.org. Details of the publisher’s procedures concerning duplication, fraud or other unethical procedures (of which Inflammopharmacology is complaint) can be found at: Publishers procedures against fraud ... Human and Animal Studies Studies in humans or those involving the use of human tissues, or laboratory animals should comply with internationally acceptable standards detailed requirements of which are specified in Inflammopharmacology 15 (2007): 179-180. Studies involving investigation of pain responses or those which are inherently painful in laboratory animals should comply with the International Association for the Study of Pain (IASP) Guidelines for the Use of Animals in Research IASP-guidelines Important note: Please follow the advice by the Editor-in-Chief in the download below: Ethics of Animal Investigations (pdf, 7 kB) Studies with Natural Products There are specific requirements for studies involving investigations of natural products or nutraceuticals, details of which can be found in Inflammopharmacology (2007): 15:179-180. In general, studies will only be acceptable providing the products have been fully characterised and details of chemical composition provided. The investigations must be directed to understanding the pharmacological properties (e.g. anti-inflammatory activities) of the test substance with comprehensive supporting data including full dose-(in vivo) or concentration (in vitro) responses to the test agents. Studies should also include investigations of the major isolated or chemically-known components in the test materials or reference to those in the Discussion. Under no circumstances will papers be acceptable if they have involved simple screening of plant or other natural product extracts for biological activities. The submitted paper must clearly show how the study will result in advances for medical treatments. Important note Please follow the advice by the Editor-in-Chief in the download below: Submissions on Natural Products (pdf, 100 kB) Does Springer provide English language support?  Manuscripts that are accepted for publication will be checked by our copyeditors for spelling and formal style. This may not be sufficient if English is not your native language and substantial editing would be required. In that case, you may want to have your manuscript edited by a native speaker prior to submission. A clear and concise language will help editors and reviewers concentrate on the scientific content of your paper and thus smooth the peer review process. The following editing service provides language editing for scientific articles in all areas Springer publishes in. Use of an editing service is neither a requirement nor a guarantee of acceptance for publication. Please contact the editing service directly to make arrangements for editing and payment. For Authors from China 文章在投稿前进行专业的语言润色将对作者的投稿进程有所帮助。作者可自愿选择使用Springer推荐的编辑服务，使用与否并不作为判断文章是否被录用的依据。提高文章的语言质量将有助于审稿人理解文章的内容，通过对学术内容的判断来决定文章的取舍，而不会因为语言问题导致直接退稿。作者需自行联系Springer推荐的编辑服务公司，协商编辑事宜。 理文编辑 For Authors from Japan ジャーナルに論文を投稿する前に、ネイティブ・スピーカーによる英文校閲を希望されている方には、Edanz社をご紹介しています。サービス内容、料金および申込方法など、日本語による詳しい説明はエダンズグループジャパン株式会社の下記サイトをご覧ください。 エダンズ グループ ジャパン For Authors from Korea 영어 논문 투고에 앞서 원어민에게 영문 교정을 받고자 하시는 분들께 Edanz 회사를 소개해 드립니다. 서비스 내용, 가격 및 신청 방법 등에 대한 자세한 사항은 저희 Edanz Editing Global 웹사이트를 참조해 주시면 감사하겠습니다. Edanz Editing Global Conflict of interest  Authors must indicate whether or not they have a financial relationship with the organization that sponsored the research. This note should be added in a separate section before the reference list. If no conflict exists, authors should state: The authors declare that they have no conflict of interest. Editorial Board Editor-in-Chief K.D. Rainsford Biomedical Research Centre Sheffield Hallam University Howard Street Sheffield, S1 1WB United Kingdom E-mail: editor@inflammopharmacology.com Fax: +44 114 225-2020 Assistant Editors Clinical Studies W.F. Kean Department of Medicine McMaster University Faculty of Health Sciences Hamilton, Ontario L8N 1T8 Canada E-mail: keanmac@cogeco.ca Basic Science R. Radhakrishnan College of Pharmacy Roseman University of Health Sciences Utah Campus 10920 S. River Front Pkwy South Jordan, UT 84095 USA E-mail: rradhakrishnan@roseman.edu Pain I.W. Rodger Professor Emeritus Department of Medicine McMaster University 1280 Main Street West Hamilton, Ontario L8S 4K1 Canada E-mail: rodgeri@mcmaster.ca Biologics A.J.K. Östör Consultant Rheumatologist & Associate Lecturer School of Clinical Medicine University of Cambridge Director, Rheumatology Clinical Research Unit Box 194, Addenbrooke’s Hospital Cambridge University Hospitals NHS Foundation Trust Hills Rd, Cambridge, CB2 2QQ United Kingdom andrew.ostor@addenbrookes.nhs.uk Section Editors Drug-Disease Interactions - Conditional Pharmacology M.C. Powanda M/P Biomedical Consultants LLC, Mill Valley, CA, USA M.W. Whitehouse School of  Medicine, Griffith University, Brisbane, Qld., Australia Gastroenterology L. Lichtenberger Dept. of Integrative Biology & Pharmacology, Health Science Center of Houston Medical School, Houston, TX, USA HECPS Representative B. Sperlagh Hungarian Academy of Sciences, Budapest, Hungary Inflammatory Mechanisms D. Cooper The William Harvey Research Institute, Barts and The Queen Mary's School of Medicine and Dentistry, London, UK D. R. Haynes Discipline of Anatomy and Pathology, University of Adelaide, Adelaide, SA, Australia Natural Products G. M. Halpern Hong Kong Polytechnic University, Kowloon, Hong Kong, China Neuroinflammation P. Khansari California Northstate College of Pharmacy, Rancho Cordova, CA, USA New Drug Developments S.A. Laufer Pharmaceutical Institute, University of Tübingen, Tübingen, Germany I.M. Hunneyball Evotec, Oxfordshire, UK Oral and Maxillofacial Pharmacology B. D. Zeitlin University of the Pacific, Arthur A. Dugoni School of Dentistry, Department of Biomedical Sciences, San Francisco, CA, USA Probiotics in Gastroenterology I. Bjarnason King's College Hospital and Medical School, London, UK Rheumatology W.F. Kean McMaster University, Hamilton, ON, Canada Regional Editors India S.K. Kulkarni University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India Middle-East J.N. Sharma Dept. of Applied Therapeutics, Faculty of Pharmacy, Health Sciences Centre, Kuwait University, Safat, Kuwait North America R. Radhakrishnan College of Pharmacy, Roseman University of Health Sciences - Utah Campus, South Jordan, UT, USA Editorial Consultants N. Bellamy (Brisbane, Qld., Australia) B.A. Callingham (Cambridge, UK) G.M. Halpern (Kowloon, Hongkong, China) R.H. Hunt (Hamilton, ON, Canada) W.F. Kean (Hamilton, ON, Canada) G. Mozsik (Pécs, Hungary) I.T. Padol (Hamilton, ON, Canada) M.P. Seed (London, UK) S. Szabo (Los Angeles, CA, USA) K. Takeuchi (Kyoto, Japan) G. Velo (Verona, Italy) B. Vernon-Roberts (Adelaide, Australia) M.W. Whitehouse (Brisbane, Qld., Australia) Editorial Board O.M.E Abdel-Salam (Cairo, Egypt) T. Arakawa (Osaka, Japan) S. Ayoub (London, UK) I. Bjarnason (London, UK) P.M. Brooks (Melbourne, Vic., Australia) C.H. Cho (Hong Kong, China) F. Chung (London, UK) D. Cooper (London, UK) L. Filaretova (St.Petersburg, Russia) D.E. Furst (Seattle,WA, USA) I. Ginsburg (Jerusalem, Israel) K. Gyires (Budapest, Hungary) C.-R. Hung (Tainan, Taiwan) R.H. Hunt (Hamilton. ON, Canada) M. Jacob, (Vellore, India) W.F. Kean (Hamilton, ON, Canada) S.K. Kulkarni (Chandigarh, India) C.-S. Lau (Hong Kong, China) T. Leung (Hong Kong, China) H.F. Miranda (Santiago, Chile) N. Moore (Bordeaux, France) K. Nishioka (Kanagawa, Japan) K. Ohuchi (Sendai, Japan) S. Okabe (Kyoto, Japan) M.C. Powanda (Mill Valley, CA, USA) R. Radhakrishnan (South Jordan, UT, USA) I. W. Rodger (Hamilton, ON, Canada) J.N. Sharma (Safat, Kuwait) B. Sperlagh, (Budapest, Hungary) B.D. Zeitlin (San Francisco, CA , USA)